Caplin Point Laboratories Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w144wnqb81cc67xn0qeggk66.pdf

Key Takeaways


Caplin Steriles: The Growth Engine

C. C. Paarthipan: "Top line is vanity. Bottom line is sanity. Cash in the bank is king."

LATAM & Core Business Dynamics

C. C. Paarthipan: "The smaller geographies that are considered insignificant by the major companies have become the center of gravity for our core business."

US & Regulated-Market Pipeline


Oncology & API: The Next Leg


Margins, Costs & Capital Allocation

D. Muralidharan: "About couple of years back when we took over the channel partners and then brought them into fold, there was some concern about the expenses going up and what not, it is all bearing fruits now and everybody is contributing and then we have been able to contain the expenses at manageable levels and that has shown in the flow of 75% in increasing contribution margin to the PBT directly."

Strategic Ambitions & New Bets

C. C. Paarthipan: "I am sure in five to six years from now we will be the number one company. In all humility I can claim that we can do it."

Guidance & Commitments

CommitmentSpecificsTimeline
Caplin Steriles FY24 revenueClose to or exactly ₹300 crores, contingent on one APIFY24 (API arrival within 10 days of call)
US FDA product approvalsMost of 14 products under active review to be approvedWithin next 12 months
US state licensingLicenses to distribute on own label in all 50 statesWithin next 8 months
US initial product launchesAround 6-7 productsWithin first year of front-end operation
Oncology tablets/capsules commercializationCommercial production startBefore March 2024
Oncology injectables and API facility completionFacility ready8-10 months from February 2024
Double-chamber PFS market entryMachinery installed March/April, then 6-9 months registrationLate 2024 / early 2025
CSL e-log book completionDigital log book operationalMay or June 2024
CSL BMR/BPR digitizationFull digitizationBefore end of 2024
Mexico filings targetIncrease to at least 60-70 products filedBefore end of 2024
Non-US regulated-market revenueFirst revenue from Mexico, Canada, South Africa, Australia filingsWithin coming 18 months
Contribution marginMaintain around 55-56%Coming quarters

Key Metrics

MetricQ3 FY24
Revenue (consolidated)₹1,290 cr (nine months), 15% growth YoY
Gross margin56% in Q3, down from 60% in Q2; 57.1% for nine months
PAT margin26.4% for nine months, above the promised 25%
PBT growth₹90 cr increase, with 75% of contribution increase flowing to PBT
Contribution margin57.1% for nine months, above the ~55% average promised
Liquid assets₹1,550 cr, exceeding nine-month revenue of ₹1,290 cr
Surplus cash~₹800 cr available for future capex and acquisitions
Caplin Steriles revenue~₹210 cr for nine months, on track toward ~₹300 cr for FY24
Caplin Steriles EBITDA₹11.7 cr for Q3 FY24
Caplin Steriles capacity utilization70–80% of usable capacity for own products; line five more than doubled capacity
Conventional business growth~11% YoY, moderated from earlier 17–18% on a larger base
CSL nine-month sales growth40% higher than previous year
Products under active FDA review14 products, most expected to be approved within 12 months
Mexico product filings24 filed, 5 registrations received; targeting 60–70 filings by end of 2024
US front-end state licensesLicenses to distribute on own label in all 50 states expected within 8 months